GRAIL Inc

GRAL

Market cap $4.3B

Deutsche Bank appears to have set a high mark when it comes to forecasts for the S&P 500 in 2026, with a target of 8,000.

Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best times in history to build wealth—especially if you think long-term and stay grounded in time-tested principles.

MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m.

The cancer diagnostics specialist received two price target increases from separate analysts. One more than doubled his on the company.

Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detection, yet questions remain about detection rates, pricing, and broad adoption, in my view. GRAL's stock has surged 185% since my last Hold call, despite lack of FDA approval and ongoing uncertainty around reimbursement, market size, and future profitability.

GRAIL, Inc. ( GRAL ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - Chief Scientific Officer & President International Aaron Freidin - Chief Financial Officer Andrew Partridge - Chief Commercial Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Douglas Schenkel - Wolfe Research, LLC Bradley Bowers - Mizuho Securities USA LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded.

Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position of More Than $850 Million Includes Recently Completed Private Placement MENLO PARK, Calif. , Nov. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025.

Investors and a powerhouse Asian conglomerate are supporting Grail's development. The company's Galleri test offers the potential to screen for more than 50 different cancers in a single test.

MENLO PARK, Calif. , Nov. 4, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18 at 10:00 a.m.

Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs.